Results 21 to 30 of about 1,026 (172)

Real‐World Outcomes of Opti‐Hep‐D: An Innovative, Multicentre and Multidisciplinary Program Improving Hepatitis D Cascade of Care [PDF]

Liver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aim Hepatitis D virus (HDV) infection remains underdiagnosed, and real‐world data on screening and linkage to care are limited. We assessed the implementation of Opti‐Hep‐D, a publicly funded initiative for HDV management in the Spanish region of Catalonia.
Adriana Palom, Ariadna Rando‐Segura, Laura Calatayud‐Samper, Gema Fernández‐Rivas, Alicia Sellés‐Sanchez, Saray Mormeneo‐Bayo, Dúnia Pérez del Campo, Eva del Corral, Tomàs Balari, Rosa Maria Morillas, Adrià Rodríguez‐Castellano, Patricia Huelin, Carmen Lopez, Darly Salazar, Joana Villaverde, Indiana Abdo, José Castellote, Joan Carles Quer Boniquet, Carles Aracil Blanch, Andrés Marco, Maria Buti   +20 more
wiley   +2 more sources

Experimental Drugs for the Treatment of Hepatitis D [PDF]

Journal of Experimental Pharmacology, 2021
Lisa Sandmann,1 Markus Cornberg1,2 1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany; 2Centre for Individualised Infection Medicine (CiiM), Helmholtz Centre for Infection Research, Braunschweig ...
Sandmann L, Cornberg M
doaj   +2 more sources

Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort

JHEP Reports
Background & Aims: In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV ...
Victor de Lédinghen, Claire Fougerou-Leurent, Estelle Le Pabic, Stanislas Pol, Dulce Alfaiate, Karine Lacombe, Marie-Noëlle Hilleret, Caroline Lascoux-Combe, Anne Minello, Eric Billaud, Isabelle Rosa, Anne Gervais, Vlad Ratziu, Nathalie Ganne, Georges-Philippe Pageaux, Vincent Leroy, Véronique Loustaud-Ratti, Philippe Mathurin, Julie Chas, Caroline Jezequel, Sophie Métivier, Jérôme Dumortier, Jean-Pierre Arpurt, Tarik Asselah, Bruno Roche, Antonia Le Gruyer, Marc-Antoine Valantin, Caroline Scholtès, Emmanuel Gordien, Christelle Tual, Amel Kortebi, Fatoumata Coulibaly, Eric Rosenthal, Miroslava Subic-Levrero, Dominique Roulot, Fabien Zoulim, François Raffi, Laurent Alric, Patrick Miailhes, Albert Tran, Christiane Stern, Xavier Causse, Simona Tripon, Ghassan Riachi, Olivier Chazouillères, Armando Abergel, Louis d’Alteroche, Jérôme Gournay, Garance Lagadic, Patrizia Carrieri, Ségolène Brichler, Martin Siguier, Jessica Krause, Juliette Foucher, Souad Ben Ali, Magdalena Meszaros, Anne Varaut, Valérie Canva   +57 more
doaj   +2 more sources

Updates on Recent Advancements in Hepatitis D Virus Treatment [PDF]

Viruses
Hepatitis D virus (HDV) infection remains a major cause of severe liver disease among hepatitis B virus (HBV)-infected patients, contributing to accelerated progression to cirrhosis and hepatocellular carcinoma.
Ali Emre Bardak, Nazli Begum Ozturk, Merve Gurakar, Lynette Sequeira, Eda Yildiz, Enis Hikmet Ozmert, Ramazan Idilman, Ahmet Gurakar   +7 more
doaj   +2 more sources

Best practices for screening, testing, diagnosing, and treating patients with hepatitis D (delta) virus based on global expert review and recent guidelines

Antiviral Therapy
Background Hepatitis D virus (HDV) represents the most severe form of human viral hepatitis, associated with rapid progression to cirrhosis and increased liver-related mortality. Globally, an estimated 9-19 million individuals are anti-HDV positive.
Markus Cornberg, Fabien Zoulim, Robert Gish, Ira M. Jacobson, Tatyana Kushner, Pietro Lampertico, Mario Rizzetto, Cihan Yurdaydin, Michael Manns   +8 more
doaj   +2 more sources

Hepatitis Delta Virus Infection: An Overview [PDF]

Pathogens
The burden of hepatitis delta virus (HDV) infection is currently unknown and may affect 12 to 72 million people distributed across various hot spots in different regions of the globe. Screening for antibodies to HDV infection in patients positive for the
Vitor Duque, Diana Duque
doaj   +2 more sources

Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy

Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Aim: to evaluate the significance of a positive polymerase chain reaction result for hepatitis D virus RNA (HDV RNA) in liver biopsy specimens of patients with chronic hepatitis D (CHD) after completion of antiviral therapy (AVT) as a predictor of ...
P. O. Bogomolov, N. A. Shub, N. A. Gasilova, A. A. Belyakova, T. G. Lidzhieva, E. A. Kondrasheva, N. A. Barsukova, M. V. Arapova, E. A. Isaeva, S. V. Koblov, M. V. Kalashnikov, O. S. Kuzymina, A. Yu. Demyanov, A. O. Bueverov, I. V. Maev   +14 more
doaj   +2 more sources

Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update. [PDF]

J Viral Hepat
ABSTRACT Chronic hepatitis Delta (CHD) represents the most aggressive form of viral hepatitis. In the latest estimates, published in 2024 by the Polaris Observatory, the overall prevalence of the hepatitis Delta virus (HDV) in Hepatitis B surface antigen (HBsAg) + patients was estimated to be 2% worldwide, a lower figure than what was
Lampertico P, Anolli MP, Steppich K, Wedemeyer H.   +3 more
europepmc   +3 more sources

Bulevirtide for hepatitis D infection. [PDF]

Aust Prescr
europepmc   +6 more sources

The Impact of Chronic Hepatitis D Virus Infection on Health-Related Quality of Life and Fatigue: A Real-World International Study. [PDF]

J Viral Hepat
ABSTRACT As little is known about the disease burden of chronic hepatitis D virus (HDV) infection, this study examined health‐related quality of life (HRQoL) and fatigue at different disease stages. This was a real‐world quantitative cross‐sectional survey of patients in Germany, Italy, Spain and the USA.
Lampertico P, Gish RG, Reau N, Wedemeyer H, Buti M, Kaushik A, Yehoshua A, Burk C, Mirams L, Ellis H, Taylor-Whiteley T, Rock M.   +11 more
europepmc   +2 more sources